HEPATOLOGY FORUM, cilt.3, sa.1, ss.16-20, 2022 (ESCI)
Background and Aim: In this study, we aimed to assess the hemostatic and histopathological impacts of the Algan hemostatic agent (AHA) with the liver injury model.